bullish
Lenvima (Lenvatinib) – Multiple Receptor Tyrosine Kinase (RTK) Inhibitor
152 Views16 Jan 2017 14:38
In the absence of promising late stage programs that can potentially fill the revenue decline due to patent expiration of erstwhile blockbusters,...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- BAN2401 Detailed Data Presented at AAIC 2018 Validates Our Initial Concerns26 Jul 2018
- BAN2401Demonstrates Statistically Significant Clinical Data for 18 Months Study06 Jul 2018
- Merck Alliance Provides Stability to Deal With the Outcome of High Risk Alzheimer’s R&D in FY1903 Jul 2018
- Lenvima (Lenvatinib) – Multiple Receptor Tyrosine Kinase (RTK) Inhibitor16 Jan 2017
x